BPC-157 vs TB-500

Recovery & Tissue Repair

Recovery & Tissue Repair

Synthetic pentadecapeptide (15 amino acids)

Synthetic peptide fragment of Thymosin β-4

Not FDA-approved; research use only

Not FDA-approved; research use only

BPC-157 is a stable fragment derived from a protein in human gastric juice. In preclinical models it is reported to interact with several healing pathways at once, rather than a single receptor.

TB-500 is based on the actin-binding region of Thymosin Beta-4. In preclinical models it is associated with several repair-related processes rather than a single receptor.

The evidence base for BPC-157 is broad in animals but thin in humans. Dozens of rodent studies report wound, tendon, and gut healing effects, and they are reasonably consistent. However, there are no published, well-controlled human trials, so it is not possible to say whether these effects translate to people.

The evidence for TB-500 is largely preclinical. Animal and cell studies describe wound, vascular, and anti-scarring effects, but well-controlled human trials are lacking, so the effects and safety in people remain unproven.

In animal studies, BPC-157 has generally been reported as well-tolerated, with a wide margin between effective and toxic doses. This does not establish human safety. Long-term effects, drug interactions, and risks in people are unknown.

Human safety data for TB-500 is essentially absent. It is banned in competitive sport by WADA. Any reported tolerability comes from animal studies, which do not establish human safety.